Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOMELA in Combination With Fludarabine and TBI Based RIC for Haploidentical Transplantation
NCT03159702Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2017
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in hematological malignancy, sponsored by Medical College of Wisconsin. Primary endpoints: Progression-free Survival at 1 year and Serious Adverse Events at 2 years. Started Dec 2017; status: completed.
02
Drugs
melphalan
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT03159702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159702.